Published in Am J Med on March 01, 2010
Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab (2014) 0.99
Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf (2010) 0.88
Year in review: medication mishaps in the elderly. Am J Geriatr Pharmacother (2011) 0.86
The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin Endocrinol Metab (2011) 0.86
A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int (2011) 0.83
Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos (2015) 0.82
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging (2013) 0.77
Using diagnoses to describe populations and predict costs. Health Care Financ Rev (2000) 5.19
Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med (2007) 4.92
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin (2005) 2.57
Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc (2005) 2.07
Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res (2001) 2.01
Early discontinuation of treatment for osteoporosis. Am J Med (2003) 2.00
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int (2003) 1.72
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract (2006) 1.46
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin (2005) 1.33
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin (2006) 1.32
Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med (2006) 1.23
Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol (2002) 1.19
Consequences of poor compliance with bisphosphonates. Bone (2007) 1.09
Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin (2007) 0.92
Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA (2003) 12.94
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 5.25
Health plan members' views about disclosure of medical errors. Ann Intern Med (2004) 3.69
Building a virtual cancer research organization. J Natl Cancer Inst Monogr (2005) 3.60
The incidence of adverse drug events in two large academic long-term care facilities. Am J Med (2005) 3.43
Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy (2008) 2.82
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA (2011) 2.77
Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care (2005) 2.33
A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf (2012) 2.11
Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc (2008) 2.09
Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf (2007) 2.09
Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc (2004) 2.08
Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis (2007) 2.03
A critical review of methods to evaluate the impact of FDA regulatory actions. Pharmacoepidemiol Drug Saf (2013) 2.00
Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med (2010) 1.86
A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf (2012) 1.86
Validation of a surveillance case definition for arthritis. J Rheumatol (2005) 1.85
FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf (2006) 1.83
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol (2013) 1.77
Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford) (2013) 1.72
The safety of warfarin therapy in the nursing home setting. Am J Med (2007) 1.72
The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology (Oxford) (2012) 1.69
Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc (2004) 1.68
Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken) (2010) 1.68
Validity of gout diagnoses in administrative data. Arthritis Rheum (2007) 1.62
Patients and providers view gout differently: a qualitative study. Chronic Illn (2010) 1.60
Monitoring of drugs with a narrow therapeutic range in ambulatory care. Am J Manag Care (2006) 1.60
Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation). Pharmacoepidemiol Drug Saf (2004) 1.56
Trends in elective labor induction for six United States health plans, 2001-2007. J Womens Health (Larchmt) (2014) 1.54
A demonstration of the impact of response bias on the results of patient satisfaction surveys. Health Serv Res (2002) 1.52
Patterns and predictors of mammography utilization among breast cancer survivors. Cancer (2006) 1.52
Challenges of estimating health service utilization for osteoarthritis patients on a population level. J Rheumatol (2002) 1.48
Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm (2006) 1.46
Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res (2006) 1.45
Chronic disease score as a predictor of hospitalization. Epidemiology (2002) 1.43
Did Medicare Part D Affect National Trends in Health Outcomes or Hospitalizations? A Time-Series Analysis. Ann Intern Med (2015) 1.42
Isolated vasculitis of the cervix presenting as vaginal discharge. J Clin Rheumatol (2004) 1.39
Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr (2005) 1.39
Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum (2008) 1.38
Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf (2007) 1.35
Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther (2009) 1.35
Increased use of second-generation macrolide antibiotics for children in nine health plans in the United States. Pediatrics (2004) 1.28
Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf (2007) 1.27
Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med (2008) 1.25
Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med (2005) 1.23
Potentially inappropriate medication use by elderly persons in U.S. Health Maintenance Organizations, 2000-2001. J Am Geriatr Soc (2005) 1.22
Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf (2005) 1.21
Disclosure of medical errors: what factors influence how patients respond? J Gen Intern Med (2006) 1.21
Neighborhood socioeconomic status and use of colonoscopy in an insured population--a retrospective cohort study. PLoS One (2012) 1.18
Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis (2012) 1.15
Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord (2012) 1.15
Nursing home residents and enrollment in Medicare Part D. J Am Geriatr Soc (2009) 1.14
Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care (2006) 1.14
Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf (2010) 1.12
Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med (2011) 1.11
Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum (2006) 1.09
Consequences of poor compliance with bisphosphonates. Bone (2007) 1.09
Medication adherence and use of generic drug therapies. Am J Manag Care (2009) 1.08
Perceived accessibility as a predictor of youth smoking. Ann Fam Med (2008) 1.07
Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr (2005) 1.07
Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.06
Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) (2011) 1.04
Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf (2007) 1.04
Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health (2013) 1.03
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med (2013) 1.01
Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf (2013) 1.00
Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy. Med Care (2010) 0.98
Adverse drug events after hospital discharge in older adults: types, severity, and involvement of Beers Criteria Medications. J Am Geriatr Soc (2013) 0.97
Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. Paediatr Perinat Epidemiol (2012) 0.96
Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics (2011) 0.96
Gastric and duodenal safety of daily alendronate. Arch Intern Med (2002) 0.94
Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. Pediatr Pulmonol (2011) 0.93
Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm (2004) 0.92
Older women's views about prescription osteoporosis medication: a cross-sectional, qualitative study. Drugs Aging (2010) 0.91
Serum procalcitonin in systemic autoimmune diseases--where are we now? Semin Arthritis Rheum (2010) 0.91
Perceived accessibility of cigarettes among youth: a prospective cohort study. Am J Prev Med (2009) 0.91
Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiol Drug Saf (2013) 0.90
Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees. J Am Geriatr Soc (2005) 0.90
Health plan members' views on forgiving medical errors. Am J Manag Care (2005) 0.90
Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf (2012) 0.89
Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach. Am J Med (2011) 0.89
Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol (2005) 0.89
Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. J Natl Cancer Inst Monogr (2005) 0.89
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther (2013) 0.88
Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf (2010) 0.88